SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Antares Pharma, Inc. - ATRS

NEW YORK, Oct. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Antares and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On October 12, 2017, post-market, Antares disclosed that on October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration ("FDA"), stating that the FDA had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Antares's lead product XYOSTED.

On this news, the Company's share price fell $1.41, or 37.80%, to close at $2.32 on October 13, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-antares-pharma-inc--atrs-300539332.html

SOURCE Pomerantz LLP